keyword
https://read.qxmd.com/read/38652072/investigation-of-basolateral-targeting-micelles-for-drug-delivery-applications-in-polycystic-kidney-disease
#1
JOURNAL ARTICLE
Yi Huang, Ali Osouli, Jessica Pham, Valeria Mancino, Colette O'Grady, Taranatee Khan, Baishali Chaudhuri, Nuria M Pastor-Soler, Kenneth R Hallows, Eun Ji Chung
Autosomal dominant polycystic kidney disease (ADPKD) is a complex disorder characterized by uncontrolled renal cyst growth, leading to kidney function decline. The multifaceted nature of ADPKD suggests that single-pathway interventions using individual small molecule drugs may not be optimally effective. As such, a strategy encompassing combination therapy that addresses multiple ADPKD-associated signaling pathways could offer synergistic therapeutic results. However, severe off-targeting side effects of small molecule drugs pose a major hurdle to their clinical transition...
April 23, 2024: Biomacromolecules
https://read.qxmd.com/read/38646391/renal-lymphangiectasia-the-transcending-of-serendipity
#2
Gina Paola Ricardo Ossio, Diana Marcela Gallo Orjuela, Juanita Salazar Agudelo, Camilo Gonzalez Gomez, Dennys Tenelanda Lopez
Renal lymphangiectasia, a rare entity of the renal lymphatic system affecting both genders and all ages, can manifest bilaterally or unilaterally and has been referred to by various terms, such as renal lymphangiomatosis, renal lymphangioma, and others. Distinguishing this condition from common pathologies, such as polycystic kidney disease or hydronephrosis, is crucial. This article presents an innovative clinical case of unilateral renal lymphangiectasia in a 67-year-old woman with a relevant medical history...
March 2024: Curēus
https://read.qxmd.com/read/38642428/the-anoctamins-structure-and-function
#3
JOURNAL ARTICLE
Rainer Schreiber, Jiraporn Ousingsawat, Karl Kunzelmann
When activated by increase in intracellular Ca2+ , anoctamins (TMEM16 proteins) operate as phospholipid scramblases and as ion channels. Anoctamin 1 (ANO1) is the Ca2+ -activated epithelial anion-selective channel that is coexpressed together with the abundant scramblase ANO6 and additional intracellular anoctamins. In salivary and pancreatic glands, ANO1 is tightly packed in the apical membrane and secretes Cl- . Epithelia of airways and gut use cystic fibrosis transmembrane conductance regulator (CFTR) as an apical Cl- exit pathway while ANO1 supports Cl- secretion mainly by facilitating activation of luminal CFTR and basolateral K+ channels...
April 15, 2024: Cell Calcium
https://read.qxmd.com/read/38641658/calcium-signalling-and-transport-in-the-kidney
#4
REVIEW
Alexander Staruschenko, R Todd Alexander, Michael J Caplan, Daria V Ilatovskaya
The kidney plays a pivotal role in regulating calcium levels within the body. Approximately 98% of the filtered calcium is reabsorbed in the nephron, and this process is tightly controlled to maintain calcium homeostasis, which is required to facilitate optimal bone mineralization, preserve serum calcium levels within a narrow range, and support intracellular signalling mechanisms. The maintenance of these functions is attributed to a delicate balance achieved by various calcium channels, transporters, and calcium-binding proteins in renal cells...
April 19, 2024: Nature Reviews. Nephrology
https://read.qxmd.com/read/38638405/youtube-tm-as-a-source-of-information-on-autosomal-dominant-polycystic-kidney-disease-a-quality-analysis
#5
JOURNAL ARTICLE
Tamer Selen, Ozgur Merhametsiz
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in adults. As a social media platform, YouTube has tremendous potential to both support and hinder public health efforts. The aim of this study was to assess the reliability and quality of the most viewed English-language YouTube videos on ADPKD. METHODS: A YouTube search was conducted on 3 August 2023, using the keyword ADPKD disease and the top 200 videos were analyzed for relevance...
2024: Digital Health
https://read.qxmd.com/read/38634253/the-arpkd-protein-dzip1l-regulates-ciliary-protein-entry-by-modulating-the-architecture-and-function-of-ciliary-transition-fibers
#6
JOURNAL ARTICLE
Huicheng Chen, Zhimao Wu, Ziwei Yan, Chuan Chen, Yingying Zhang, Qiaoling Wang, Yuqing Gao, Kun Ling, Jinghua Hu, Qing Wei
Serving as the cell's sensory antennae, primary cilia are linked to numerous human genetic diseases when they malfunction. DZIP1L, identified as one of the genetic causes of human autosomal recessive polycystic kidney disease (ARPKD), is an evolutionarily conserved ciliary basal body protein. Although it has been reported that DZIP1L is involved in the ciliary entry of PKD proteins, the underlying mechanism remains elusive. Here, an uncharacterized role of DZIP1L is reported in modulating the architecture and function of transition fibers (TFs), striking ciliary base structures essential for selective cilia gating...
April 17, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38634129/raising-serum-uric-acid-with-a-uricase-inhibitor-worsens-pkd-in-rat-and-mouse-models
#7
JOURNAL ARTICLE
Anjana Chaudhary, Zhibin He, Daniel J Atwood, Makoto Miyazaki, Ozgur A Oto, Allen Davidoff, Charles L Edelstein
Humans are predisposed to gout because they lack uricase that converts uric acid to allantoin. Rodents have uricase, resulting in low basal serum uric acid. A uricase inhibitor raises serum uric acid in rodents. There were 2 aims of the study in polycystic kidney disease (PKD): 1) to determine whether increasing serum uric acid with the uricase inhibitor, oxonic acid, resulted in faster cyst growth and 2) to determine whether treatment with the xanthine oxidase inhibitor, oxypurinol, reduced the cyst growth caused by oxonic acid...
April 18, 2024: American Journal of Physiology. Renal Physiology
https://read.qxmd.com/read/38633811/cfap47-is-a-novel-causative-gene-implicated-in-x-linked-polycystic-kidney-disease
#8
Takayasu Mori, Takuya Fujimaru, Chunyu Liu, Karynne Patterson, Kouhei Yamamoto, Takefumi Suzuki, Motoko Chiga, Akinari Sekine, Yoshifumi Ubara, Danny E Miller, Miranda Galey, Shintaro Mandai, Fumiaki Ando, Yutaro Mori, Hiroaki Kikuchi, Koichiro Susa, Jessica X Chong, Michael J Bamshad, Yue-Qiu Tan, Feng Zhang, Shinichi Uchida, Eisei Sohara
Autosomal dominant polycystic kidney disease (ADPKD) is a well-described condition in which ~80% of cases have a genetic explanation, while the genetic basis of sporadic cystic kidney disease in adults remains unclear in ~30% of cases. This study aimed to identify novel genes associated with polycystic kidney disease (PKD) in patients with sporadic cystic kidney disease in which a clear genetic change was not identified in established genes. A next-generation sequencing panel analyzed known genes related to renal cysts in 118 sporadic cases, followed by whole-genome sequencing on 47 unrelated individuals without identified candidate variants...
April 5, 2024: medRxiv
https://read.qxmd.com/read/38621633/kidney-energetics-and-cyst-burden-in-autosomal-dominant-polycystic-kidney-disease-a-pilot-study
#9
JOURNAL ARTICLE
Petter Bjornstad, Gabriel Richard, Ye Ji Choi, Kristen L Nowak, Cortney Steele, Michel B Chonchol, Kristen J Nadeau, Timothy Vigers, Laura Pyle, Kalie Tommerdahl, Daniel H van Raalte, Allison Hilkin, Lynette Driscoll, Carissa Birznieks, Katharina Hopp, Wei Wang, Charles Edelstein, Robert G Nelson, Adriana V Gregory, Timothy L Kline, Denis Blondin, Berenice Gitomer
RATIONALE & OBJECTIVE: In this pilot study, we hypothesized that autosomal dominant polycystic kidney disease (ADPKD) is characterized by impaired kidney oxidative metabolism that associates with kidney size and cyst burden. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: Twenty adults with ADPKD (31±6 years of age, 65% women, BMI: 26.8 [22.7, 30.4] kg/m2 , eGFR (2021 CKD-EPI Creatinine): 103±18 ml/min/1.73m2 , height-adjusted total kidney volume [HtTKV]: 731±370 ml/m, Mayo Classifications: 1B [5%], 1C [42%], 1D [21%], 1E [32%]) and 11 controls in normal weight category (NWC; 25±3 years of age, 45% women, BMI: 22...
April 13, 2024: American Journal of Kidney Diseases
https://read.qxmd.com/read/38618918/investigational-agents-for-autosomal-dominant-polycystic-kidney-disease-preclinical-and-early-phase-study-insights
#10
REVIEW
Irene Capelli, Sarah Lerario, Francesca Ciurli, Gian Marco Berti, Valeria Aiello, Michele Provenzano, Gaetano Manna
INTRODUCTION: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney condition caused by a single gene mutation. It leads patients to kidney failure in more than 50% of cases by the age of 60, and, given the dominant inheritance, this disease is present in the family history in more than 90% of cases. AREAS COVERED: This review aims to analyze the set of preclinical and early phase studies to provide a general view of the current progress on ADPKD therapeutic options...
April 15, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38616607/renal-pathology-of-ciliopathies
#11
JOURNAL ARTICLE
Thivya Sekar, Neil J Sebire
Renal ciliopathies are a group of genetic disorders that affect the function of the primary cilium in the kidney, as well as other organs. Since primary cilia are important for regulation of cell signaling pathways, ciliary dysfunction results in a range of clinical manifestations, including renal failure, cyst formation, and hypertension. We summarize the current understanding of the pathophysiological and pathological features of renal ciliopathies in childhood, including autosomal dominant and recessive polycystic kidney disease, nephronophthisis, and Bardet-Biedl syndrome, as well as skeletal dysplasia associated renal ciliopathies...
April 14, 2024: Pediatric and Developmental Pathology
https://read.qxmd.com/read/38616432/long-term-effectiveness-and-safety-of-tolvaptan-in-autosomal-dominant-polycystic-kidney-disease
#12
JOURNAL ARTICLE
Lorenzo Cantarelli, Marta Gutiérrez Valencia, Leire Leache Alegria, Luis Carlos Sainz Fernandez, Juan Erviti Lopez, Fernando Gutiérrez Nicolas, Gloria Julia Nazco Casariego
BACKGROUND AND OBJECTIVES: Evidence on the long-term use of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) is limited. The aim was to evaluate the tolvaptan effectiveness and safety in real clinical setting. MATERIAL AND METHODS: A single-center observational study (2016-2022) involving ADPKD patients treated with tolvaptan was conducted. Annual change in serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) before and after treatment initiation were evaluated...
April 13, 2024: Medicina Clínica
https://read.qxmd.com/read/38616285/carnitine-palmitoyltransferase-ii-cpt-ii-deficiency-responsible-for-refractory-cardiac-arrhythmias-acute-multiorgan-failure-and-early-fatal-outcome
#13
JOURNAL ARTICLE
Gregorio Serra, Vincenzo Antona, Vincenzo Insinga, Giusy Morgante, Alessia Vassallo, Simona La Placa, Ettore Piro, Sergio Salerno, Ingrid Anne Mandy Schierz, Eloisa Gitto, Mario Giuffrè, Giovanni Corsello
BACKGROUND: Carnitine palmitoyltransferase II (CPT II) deficiency is a rare inborn error of mitochondrial fatty acid metabolism with autosomal recessive pattern of inheritance. Its phenotype is highly variable (neonatal, infantile, and adult onset) on the base of mutations of the CPT II gene. In affected subjects, long-chain acylcarnitines cannot be subdivided into carnitine and acyl-CoA, leading to their toxic accumulation in different organs. Neonatal form is the most severe, and all the reported patients died within a few days to 6 months after birth...
April 14, 2024: Italian Journal of Pediatrics
https://read.qxmd.com/read/38614778/genomics-in-the-kidney-clinic
#14
JOURNAL ARTICLE
Gabriel T Doctor, Daniel P Gale, Melanie My Chan
Inherited diseases are a frequent cause of end-stage kidney disease and often seen in the kidney clinic. Clinical genomic testing is increasingly available in the UK and eligible patients in England can be referred through the NHS Genomic Medicine Service. Testing is useful for diagnosis, prognostication and management of conditions such as autosomal dominant polycystic kidney disease (ADPKD), Alport syndrome, autosomal dominant tubulointerstitial kidney disease (ADTKD) and focal segmental glomerulosclerosis (FSGS)...
May 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/38608748/visceral-adiposity-and-progression-of-adpkd-a-cohort-study-of-patients-from-the-tempo-3-4-trial
#15
JOURNAL ARTICLE
Kristen L Nowak, Federica Moretti, Nicole Bussola, Cortney Steele, Adriana V Gregory, Timothy L Kline, Sumana Ramanathan, Giovanni Trapletti, Cesare Furlanello, Linda McCormick, Michel Chonchol
RATIONALE & OBJECTIVE: Body-mass index (BMI) is an independent predictor of kidney disease progression in individuals with autosomal dominant polycystic kidney disease (ADPKD). Adipocytes do not simply act as a fat reservoir but are active endocrine organs. We hypothesized that greater visceral abdominal adiposity would associate with more rapid kidney growth in ADPKD and influence the efficacy of tolvaptan. STUDY DESIGN: A retrospective cohort study. SETTING & PARTICIPANTS: 1053 patients enrolled in the TEMPO 3:4 tolvaptan trial with ADPKD and high risk of rapid disease progression...
April 10, 2024: American Journal of Kidney Diseases
https://read.qxmd.com/read/38607049/polycystin-2-mediated-calcium-signalling-in-the-dictyostelium-model-for-autosomal-dominant-polycystic-kidney-disease
#16
JOURNAL ARTICLE
Claire Y Allan, Oana Sanislav, Paul R Fisher
Autosomal dominant polycystic kidney disease (ADPKD) occurs when the proteins Polycystin-1 (PC1, PKD1 ) and Polycystin-2 (PC2, PKD2 ) contain mutations. PC1 is a large membrane receptor that can interact and form a complex with the calcium-permeable cation channel PC2. This complex localizes to the plasma membrane, primary cilia and ER. Dysregulated calcium signalling and consequential alterations in downstream signalling pathways in ADPKD are linked to cyst formation and expansion; however, it is not completely understood how PC1 and PC2 regulate calcium signalling...
March 31, 2024: Cells
https://read.qxmd.com/read/38606040/treatment-for-patients-with-autosomal-dominant-polycystic-kidney-disease-in-the-chronic-kidney-disease-without-kidney-replacement-therapy-in-real-world-clinical-practice-a-descriptive-retrospective-cohort-study
#17
JOURNAL ARTICLE
Kazunori Sakoda, Kayoko Mizuno, Tomotsugu Seki, Kanna Shinkawa, Yuriko Kawai, Ayano Hayashi, Satomi Yoshida, Masato Takeuchi, Motoko Yanagita, Koji Kawakami
BACKGROUND: In real-world clinical practice, treatments selected for patients with autosomal dominant polycystic kidney disease (ADPKD) in the chronic kidney disease (CKD) without kidney replacement therapy (KRT) have not been reported. This study investigated the oral treatments used in these patients and the changes in their use in recent years. Additionally, we studied the factors affecting tolvaptan dose reduction or discontinuation. METHODS: This retrospective cohort study was conducted using the medical records of 160 hospitals in Japan...
2024: Ann Clin Epidemiol
https://read.qxmd.com/read/38604258/notch3-as-a-novel-therapeutic-target-for-the-treatment-of-adpkd-by-regulating-cell-proliferation-and-renal-cyst-development
#18
JOURNAL ARTICLE
Limin Su, Ting Chen, Hongtao Hu, Zifan Xu, Xiande Luan, Kequan Fu, Ying Ren, Dong Sun, Ying Sun, Dong Guo
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic kidney disease. Emerging research indicates that the Notch signaling pathway plays an indispensable role in the pathogenesis of numerous kidney diseases, including ADPKD. Herein, we identified that Notch3 but not other Notch receptors was overexpressed in renal tissues from mice with ADPKD and ADPKD patients. Inhibiting Notch3 with γ-secretase inhibitors, which block a proteolytic cleavage required for Notch3 activation, or shRNA knockdown of Notch3 significantly delayed renal cyst growth in vitro and in vivo...
April 10, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38599980/the-pathophysiology-of-polycystic-liver-disease
#19
JOURNAL ARTICLE
Renée Duijzer, Melissa M Boerrigter, Tom J G Gevers, Joost P H Drenth
No abstract text is available yet for this article.
April 9, 2024: Journal of Hepatology
https://read.qxmd.com/read/38596265/prevalence-and-outcomes-of-polycystic-kidney-disease-in-african-populations-a-systematic-review
#20
JOURNAL ARTICLE
Modou Ndongo, Lot Motoula Nehemie, Baratou Coundoul, Abou Abdallah Malick Diouara, Sidy Mohamed Seck
BACKGROUND: Polycystic kidney disease (PKD) is the most common genetic cause of kidney disease. It is a progressive and irreversible condition that can lead to end-stage renal disease and many other visceral complications. Current comprehensive data on PKD patterns in Africa is lacking. AIM: To describe the prevalence and outcomes of PKD in the African population. METHODS: A literature search of PubMed, African journal online, and Google Scholar databases between 2000 and 2023 was performed...
March 25, 2024: World Journal of Nephrology
keyword
keyword
10515
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.